摘要
创伤性脑损伤(TBI)是交通事故中导致死亡和残疾的主要原因之一,传统神经保护治疗方法不能显著改善患者的神经功能。骨髓间充质干细胞(BMSCs)外泌体作为一种新的治疗策略,因其抗炎、抗凋亡和神经保护等功能,显示出潜在的治疗优势。外泌体通过携带促血管生成因子和神经营养因子,促进血管生成和神经再生,调节神经炎症,从而减轻TBI引起的神经损伤。然而,外泌体治疗仍面临剂量不确定、TBI异质性影响和分离纯化技术不成熟等挑战。未来研究需进一步优化外泌体的分离技术,明确最佳治疗剂量和时机,深入探讨其靶向机制,以推动BMSCs外泌体在TBI治疗中的应用。
Traumatic brain injury(TBI)is one of the leading causes of death and disability in traffic accidents,and traditional neuroprotective treatment methods cannot significantly improve neurological function in the patients.As a new therapeutic strategy,bone marrow mesenchymal stem cells(BMSCs)-derived exosomes have shown potential therapeutic advantages due to their anti-inflammatory,anti-apoptotic,and neuroprotective functions.The exosomes promote angiogenesis and neurogenesis,regulate neuroinflammation,and thus reduce neural damage caused by TBI by carrying pro-angiogenic factors and neurotrophic factors.However,exosome therapy still faces challenges such as uncertain dosage,the impact of TBI heterogeneity,and immature isolation and purification technology.Future research needs to further optimize exosome isolation technology,determine the optimal therapeutic dosage and timing,and delve into the targeting mechanisms,so s to promote the clinical application of BMSCs-derived exosomes in TBI treatment.
作者
李树
鲍勇钢
吴彬
LI Shu;BAO Yonggang;WU Bin(School of Clinical Medicine,Jining Medical University,Jining 272000,China;Department of Traumatology,Affiliated Hospital of Jining Medical University,Jining 272000,China)
出处
《医学综述》
CAS
2024年第19期2354-2358,共5页
Medical Recapitulate
基金
济宁医学院高层次科研项目培育计划(JYGC2021FKJ016)
济宁市重点研发计划项目(2021YXNS029,2022YXNS129)
济宁医学院附属医院“主诊医师团队专项临床研究计划”项目(ZZTD-MS-2023-04)。
关键词
创伤性脑损伤
骨髓间充质干细胞
外泌体
Traumatic brain injury
Bone marrow mesenchymal stem cells
Exosomes
